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conditions were more frequent in parents with NEs related to work or friends. 
CONCLUSIONS: PWH with one NE were more likely to report other NEs. 
PWH/parents with NEs reported greater social worker involvement and 
treatment for psychological conditions. Further studies are needed to assess 
temporal relationships between NEs and HTC visits/advice, and support the 
relevance of timely social work and psychological counselling in comprehensive 
care.  
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HEALTH AND WELLNESS SURVEY (NHWS)  
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OBJECTIVES: Pain is not a disease, but might be a symptom of a disease, the 
effect of a disease or an accident. It pervades a person’s daily life activities, social 
interaction and productive hours. It has powerful psychological and social 
consequences. In Russia, there are no solid estimates of the magnitude of the 
condition. This study is aimed to assess co-morbidity, quality of life (QOL), 
work/productivity loss, and resource utilization in Russian urban adults with 
pain. METHODS: Patients’ self-reported data were collected from 2011 National 
Health and Wellness Survey (NHWS). Survey represented major urban areas in 
Russia. QOL was measured by the physical (PCS) and mental (MCS) component 
summary scores of the (SF-12v2). Loss of work/productivity was measured by the 
Work Productivity and Activity Impairment instrument. Medical resource 
utilization was measured by health care provider, ambulance request and 
hospitalization in the past 6 months. RESULTS: Of the 10,039 adult respondents, 
2,670 (28%) reported to experience pain over the past month (17% mild, 54% 
moderate and 28% severe) – 35% not receiving medication at all. Average age of 
patients experiencing pain was 41.5 years. Pain group reported more co-
morbidities (headaches 77%, sleep difficulties 54%, insomnia 47%, heartburn 45%, 
depression 39%, high blood pressure 33%), lower mean scores of PCS (43.4 
vs.47.8) and MCS (40.0 vs. 45.0), more patients visited health care providers (83% 
vs. 67%), and a higher percentage were hospitalized (13% vs. 8%) over the past 6 
months compared to no experiencing pain group. Furthermore, pain group 
reported 35.9% impairment in daily activity compared to 23.0% in no 
experiencing pain group. All mentioned differences were statistically significant 
(p < 0.05) and all percentages or means are projected values. CONCLUSIONS: 
From Russian NHWS results, patients experiencing pain suffer from impairment 
in QOL, work/productivity loss and more co-morbidities. Findings indicate there 
is still an unmet medical need in Russian patients with pain.  
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TREATMENT OPTIONS IN OBESITY: IS CLINICAL DEVELOPMENT KEEPING UP 
WITH AN EXPANDING POPULATION?  
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OBJECTIVES: The occurrence of obesity in the UK is rapidly increasing, and is 
associated with significant health problems and economic costs. Despite this, 
there is currently only one drug recommended by NICE for the treatment of 
obesity. The purpose of the study was to examine whether the clinical 
development of obesity treatments is keeping up with the increasing obese 
population in the UK. METHODS: Adult obesity prevalence data for England were 
obtained from the 2011 Health Survey for England Trend Tables. Total economic 
costs were obtained from the National Obesity Observatory. ClinicalTrials.gov 
was searched for the number of clinical trials investigating drug and device 
interventions for obesity initiated yearly from database inception to the 17th of 
January 2013. Results were reviewed to exclude trials investigating dietary 
supplements, behavioural changes, dietary changes, and those without a UK 
centre. RESULTS: The prevalence of obese adults in England has risen from 
14.9% (1993) to 24.8% (2011). This has been associated with an estimated increase 
in total costs to the UK of £2.6 billion (1998) to £15.8 billion (2007). Since 2000, 46 
trials have been initiated investigating treatments for obesity. The number of 
clinical trials initiated yearly has increased since 2000; however recent years 
have seen a decline. 1 trial was initiated in 2000, generally increasing up until 
2010 when 8 trials were initiated. 2011 and 2012 both saw a dip in the number of 
initiated trials, with only 3 trials started in 2012. CONCLUSIONS: The prevalence 
and economic burden of obesity has increased drastically in the UK over the past 
18 years. The rate of clinical development has also increased; however, this rate 
is low in relation to the significance of this health problem and the increase in 
the obese population. These results highlight the need for further clinical 
development in treating obesity.  
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IMPACTS OF BLACK BOX WARNING, NATIONAL COVERAGE DETERMINATION, 
AND RISK EVALUATION AND MITIGATION STRATEGIES ON THE INPATIENT 
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OBJECTIVES: This study aims to quantify the impact of (1) black box warning, (2) 
CMS National Coverage Determination (NCD), and (3) Risk Evaluation and 
Mitigation Strategies (REMS) on erythropoiesis-stimulating agents (ESAs) on-label 
and off-label utilization patterns among adult inpatients. METHODS: Electronic 
health records in Cerner HealthFact database from January 2005 to June 2011 
were used. Eligible patients for ESA prescribing were categorized using ICD-9-CM 
codes and medication information. The three patient categories were (1) on-label 
(ONS, conditions approved by the FDA); (2) off-label supported (OFS, strong 
clinical evidence for use in unapproved indications); and (3) off-label 
unsupported (OFU, low/no evidence supporting use in unapproved indications). 
The likelihood of receiving ESAs was assessed using a generalized estimating 
equation approach with binary logistic regression technique, clustering for 
hospitals, and controlling for potential confounders. RESULTS: We identified 
730,421 patients with ONS conditions (33,004 users, 4.5%), 505, 658 with OFS 
conditions (5,140 users, 1.0%), and 558,917 patients with OFU conditions (4,491 
users, 0.8%). Black box warning and REMS had no impact on the odds of receiving 
ESAs. There was a significant decline in all three use categories the month 
following NCD. ONS patients were 13% less likely to receive ESAs (OR 0.867, 95% 
CI 0.762, 0.986, p = 0.0299). OFS patients were 20% less likely (OR 0.799, 95% CI 
0.716, 0.891, p < 0.0001) and OFU patients were 38% less likely to receive ESAs (OR 
0.622, 95% CI 0.474, 0.817, p = 0.0006). Age, gender, race, source of payment, 
admission type, clinical complexity, discharge disposition, and hospital size were 
significantly associated with on-label and off-label use. CONCLUSIONS: We 
demonstrated the relative impact of three safety interventions on on-label and 
off-label ESA use in the hospital settings. Reimbursement change may have 
unintentionally reduced the likelihood of receiving ESAs in patients who could 
have otherwise benefited.  
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OBJECTIVES: Escalating rates of prescription opioid use and abuse have occurred 
in the context of efforts to improve the identification and management of non-
malignant pain. To characterize the diagnosis and management of non-
malignant pain in ambulatory, office-based settings between 2000 and 2010. 
METHODS: Serial cross-sectional and multivariate regression analyses of the 
National Ambulatory Medical Care Survey (NAMCS), a nationally representative 
audit of office-based physician visits. The main outcome measures were 1) 
Annual volume of visits among adults with a primary symptom or diagnosis of 
pain, and 2) prescription opioid and non-opioid pharmacologic therapy in visits 
limited to new musculoskeletal pain. RESULTS: Primary symptoms or diagnoses 
of pain consistently represented one-fifth of visits, varying less than 2% from 
2000 through 2010. Patient-reported pain comprised 17% to 19% of visits, 
whereas provider diagnoses of pain increased nearly 50% from 2000 (5.7% of 
visits with pain as a primary diagnosis) to 2010 (8.5%). Among all pain visits, 
opioid use nearly doubled from 11.3% to 19.6%, whereas use of non-opioid 
analgesics remained unchanged (26%-29% of visits). Pain medications were 
associated with one-half of new musculoskeletal pain visits, with the use of non-
opioid pharmacotherapies decreasing from 38% of visits (2000) to 29% of visits 
(2010). After adjusting for potentially confounding covariates, few patient, 
physician or practice characteristics were associated with the use of non-opioid 
rather than opioid analgesia. CONCLUSIONS: Increased opioid use during the 
past decade has not been accompanied by similar increases in non-opioid 
analgesics. Clinical alternatives to prescription opioids may be underutilized as a 
means of treating ambulatory non-malignant pain.  
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META-ANALYSIS OF NEPHROTOXICITY IN PATIENTS WITH SOLID TUMORS 
TREATED WITH CISPLATIN VERSUS NON-CISPLATIN REGIMENS WITH  
SUB-GROUP ANALYSES BASED ON RENAL ELIGIBILITY CRITERIA  
Dahal A1, Bellows BK1, Sonpavde G2, Galsky MD3, Agarwal N4 
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OBJECTIVES: Glomerular filtration rate (GFR) is known to better estimate renal 
function than serum creatinine (SCr), but SCr is commonly used when screening 
patients for inclusion into clinical trials of the nephrotoxic drug cisplatin. The 
objective of this meta-analysis was to indirectly compare incidence of 
nephrotoxicity in trials including cisplatin when renal function was assessed 
using either SCr or GFR for eligibility criteria. METHODS: A PubMed literature 
search identified randomized trials comparing cisplatin to non-cisplatin 
regimens. Included studies were performed from 1990-2010, used SCr or GFR as 
inclusion criteria, and reported incidence of WHO grade ≥3 nephrotoxic events 
for both treatment arms. Review articles, observational studies, phase 1 studies, 
non-randomized trials, studies without a comparator group, or studies not 
reported in English were excluded. Inverse variance weighted fixed effects (FE) 
and random effects (RE) methods were used to estimate the relative risk (RR) 
associated with cisplatin versus non-cisplatin regimens with sub-group analyses 
of studies using SCr, GFR, and either SCr or GFR for screening. RESULTS: A total 
of 2,359 studies were identified from the literature search and 29 studies met all 
inclusion and exclusion criteria (N=6,146 patients). Of these, 18 studies used SCr 
(N=4,146), 5 used GFR (N=993), and 6 used SCr or GFR (N=1,007) for screening. The 
overall RR for developing nephrotoxicity with cisplatin versus non-cisplatin 
treatment was 2.09 (95%CI 1.33-3.27, p=0.001). In sub-group analyses, the RR was 
2.47 (95%CI 1.24-4.94, p=0.011) for SCr, 1.84 (95%CI 0.96-3.54, p=0.067) for GFR, and 
1.88 (95%CI 0.49-7.26, p=0.359) for either SCr or GFR. Results did not vary between 
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FE and RE methods. CONCLUSIONS: Cisplatin significantly increased the RR of 
nephrotoxicity compared to non-cisplatin regimens when SCr was used to 
screen patients for inclusion in clinical trials, but only showed a trend toward a 
smaller increase in RR when GFR was used.  
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OBJECTIVES: To examine the clinical characteristics and treatment patterns of 
colorectal cancer patients in the U.S. veteran population. METHODS: A study 
sample from the Veterans Health Administration (VHA) Medical SAS datasets 
from October 1, 2005 through May 31, 2012 was analyzed. All patients diagnosed 
with colorectal cancer throughout the study period were identified using 
International Classification of Disease 9thRevision Clinical Modification (ICD-9-
CM) diagnosis codes 153.xx and 154.xx. Descriptive statistical analyses were 
performed using SAS v9.3 software. RESULTS: There were 62,200 diagnosed 
colorectal cancer patients in the VHA population during the study period. Major 
comorbidities for these colorectal cancer patients were hypertension (n=18,309, 
29.44%) and diabetes (n=10,891, 17.51%). Other minor comorbidities included 
hyperlipidemia and benign neoplasm of the colon. Common treatments 
prescribed for colorectal cancer patients were simvastatin and omeprazole. 
Outpatient services were utilized by 99.71% of colorectal cancer patients, 
followed by pharmacy (91.94%) and inpatient visits (31.15%). Costs for outpatient 
($10,637, standard deviation [SD]=$17,125), pharmacy ($2,704, SD=$9,773), and 
inpatient services ($16,032, SD=$53,078) contributed to follow-up health care 
expenditures. Out of all colorectal cancer patients, 7,596 (12.21%) had Occult 
Blood (Fecal) Test results, with an average test result of 96.37. CONCLUSIONS: 
Colorectal cancer treatment is complicated by the presence of both major and 
minor comorbidities. Further analysis in the context of complicated comorbid 
conditions is required to improve the overall burden of illness of colorectal 
cancer patients.  
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OBJECTIVES: To examine the economic burden and clinical characteristics of 
lung cancer in the U.S. veteran population. METHODS: A retrospective database 
analysis was performed using the Veterans Health Administration (VHA) Medical 
SAS Datasets from October 1, 2005 to May 31, 2012. Patients with lung cancer 
were identified using International Classification of Disease 9th Revision Clinical 
Modification (ICD-9-CM) diagnosis code 162.xx. Descriptive statistics were 
calculated as means ± standard deviation (SD) and percentages to measure 
comorbidities, laboratory tests, costs and utilization distribution in the sample. 
Comorbidities and laboratory tests were measured for the 1-year baseline period 
before the disease identification date. Health care costs and utilization were 
measured for the 1-year follow-up period after the identification date. RESULTS: 
The total number of lung cancer patients identified in the study period was 
73,150. The most common comorbidities of these patients were hypertension 
(n=21,377, 29.22%), chronic airway obstruction (n=14,305, 19.56%), abnormal 
findings on radiological and other examination of lung field (n=12,437, 17.00%), 
and diabetes (n=11,569, 15.82%). Omeprazole and simvastatin were the top two 
most commonly prescribed treatments for lung cancer patients. Both 
medications were prescribed for more than 20% of all lung cancer patients. A 
total of 49,706 (67.95%) of the lung cancer patients had total white blood cell 
(WBC) count test results, averaging a result of 11.68. The percentage of patients 
with follow-up inpatient visits was 46.47%, which translated into $21,420 of 
inpatient costs per patient. 99.11% of patients had follow-up outpatient visits, 
which translated into $12,986 total outpatient costs per patient ($12,110 for office 
visit, $411 for emergency room visit costs). CONCLUSIONS: This study found that 
omeprazole and simvastatin were the most frequently prescribed drugs after a 
lung cancer diagnosis. However, more research is required to better understand 
adverse events and side effects.  
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RITUXIMAB FOR NON HODGKIN LYMPHOMA: OVERVIEW OF EFFICACY AND 
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OBJECTIVES: To evaluate the efficacy and safety of the monoclonal antibody 
rituximab (RIT) for the treatment of patients with indolent or aggressive non-
Hodgkin lymphoma B cells (B-NHL). METHODS: We searched The Cochrane 
Library, Centre for Reviews and Dissemination, Tripdatabase, Medline and 
LILACS databases aiming to find systematic reviews (SR) and randomized clinical 
trials (RCT) comparing RIT regimens versus RIT free regimens for induction or 
maintenance treatment of indolent and aggressive B-NHL. Health Technology 
Assessments (HTA) were searched on agencies websites. Quality of the evidence 
and strength of recommendation were evaluated using the GRADE system. 
RESULTS: We selected thirteen SR, eight RCT and six HTA publications. Half of 
the SR and the majority of RCT were classified as poor quality. The strength of 
recommendation was considered weak in favor of RIT in all studies. Combined 
overall survival meta-analysis showed a relative risk of 1.09 (1.06; 1.12) benefiting 
RIT treated patients. Overall survival for aggressive NHL non-RIT treated patients 
was 0.53 (0.37; 0.77). The death hazard ratio for indolent B-NHL RIT treated 
patients were 0.65 (0.54; 0.78) and 0.76 (0.62; 0.92). Individual studies also showed 
benefits of increased overall survival for RIT treated patients. The studies 
showed a higher incidence of serious adverse events with RIT regimens, such as 
granulocytopenia and leucopenia, which did not appear to lead to increased 
infections or mortality rates. HTA publications recommended the use of RIT 
regimens as first-line therapy for aggressive and indolent B-NHL or as second-
line therapy and maintenance for indolent B-NHL. CONCLUSIONS: Evidences 
support the use of RIT in combination with chemotherapy as first-line and 
second-line treatment for aggressive B-NHL. For patients with follicular indolent 
B-NHL, RIT is recommended in combination with chemotherapy for patients 
previously treated or not, and for the maintenance of patients who responded to 
treatment after second-line chemotherapy.  
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SYSTEMATIC REVIEW OF ANTI-VEGF THERAPIES FOR METASTATIC 
COLORECTAL CANCER  
Aggarwal S, Segal J 
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OBJECTIVES: Anti-angiogenic therapy has become an integral component of 
treatment for metastatic colorectal cancer patients. During the last 10 years, 
several studies were conducted to test the safety and efficacy of anti-angiogenic 
therapies in mCRC patients. This study reviewed the results of randomized 
controlled trials published in peer-reviewed journals. METHODS: We searched 
the MEDLINE, and abstracts from ECCO, ESMO and ASCO until January 2013. 
Studies were selected for randomized controlled trials on targeted anti-
angiogenic drugs in mCRC. Primary endpoints reviewed were progression-free 
(PFS) and overall survival (OS). Response rates, toxicity and secondary 
resectability were secondary endpoints. Aggregated data were further analyzed 
to understand comparative safety and efficacy. RESULTS: Until January 2013, 
eligible mCRC randomized clinical trials for this review were available for 
bevacizumab (6 trials including 4523 patients), Cediranib ( 2 trials including 2282 
patients), vatalanib (2 trials including 2033 patients) and aflibercept (1 trial 
including 1226 patients). Overall, anti-angiogenesis therapy for mCRC shows 
significant OS and PFS benefit versus comparators. The median OS and PFS 
benefit for regimens containing Bevacizumab were 3 and 3.15 months, versus 
background chemotherapy. The median OS and PFS benefit for vatalanib 
containing regimens were statistically insignificant versus background 
chemotherapy. CONCLUSIONS: Anti-angiogenesis therapy with Bevacizumab for 
mCRC shows significant OS and PFS benefit versus comparators.  
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OBJECTIVES: Breast cancer is the most common cancer in women as well as the 
principle cause of death from cancer among women worldwide. Approximately 
20%–30% of women with breast cancer over-express the human epidermal 
growth factor receptor 2 (HER2), which promotes the growth of cancer 
cells.Trastuzumab is a recombinant humanized monoclonal antibody that 
targets HER2. It has been shown to be effective as monotherapy and, as adjuvant 
therapy, has been shown to improve results of chemotherapy in patients with 
HER2-positive metastatic breast cancer. The objective of this study was to 
conduct a meta-analysis of the available evidence on the benefit of receiving 
adjuvant trastuzumab in HER2-positive breast cancer patients who are 
concomitantly receiving chemotherapy. METHODS: We performed a literature 
search in MEDLINE® (1996 to 2012) to find peer-reviewed publications and 
academic conference proceedings relevant to the objective. A meta-analysis of 
randomized controlled trials comparing chemotherapy patients with or without 
adjuvant trastuzumab treatment was conducted. The primary outcome was 
disease-free survival (DFS), while a secondary outcome was mortality. Both the 
random-effects model and the fixed-effect model were used to combine and 
analyze data. RESULTS: Six eligible clinical trials were identified, and 14,299 
patients with HER2-positive breast cancer were included. Results indicated 
superior outcomes in the adjuvant trastuzumab group relative to the group 
without trastuzumab. For DFS, the trastuzumab group had an odds ratio (OR) of 
0.62 (95% CI: 0.48-0.80).For mortality, it had an OR of 0.77 (95% CI: 0.64-0.93). 
CONCLUSIONS: According to the meta-analysis, adjuvant trastuzumab therapy 
both improves DFS and reduces mortality relative to patients treated with 
chemotherapy only. Other issues surrounding trastuzumab include optimum 
length of therapy, the high cost of therapy, and the high risk of cardiovascular 
side effects, which may themselves lead to death.  
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SORAFENIB FOR KIDNEY CANCER: EVIDENCE OF EFFICACY, SAFETY AND COST 
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OBJECTIVES: Evaluate the efficacy, safety and cost estimates of sorafenib 
compared to other therapeutic options for the treatment of metastatic renal cell 
carcinoma (mRCC). METHODS: Systematic reviews (SR) of clinical trials 
comparing sorafenib with other therapeutic options were searched in The 
Cochrane Library, Medline, Lilacs, Centre for Reviews and Dissemination and 
Tripdatabase. We also selected health technology assessments (HTA) reports. 
Monthly treatment costs of the inhibitors of vascular endothelial growth factor 
